Nicotinamide ribonucleoside
Phase 2Small molecule
Nicotinamide ribonucleoside is one of 7 small molecule programs targeting Ataxia-telangiectasia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Ataxia-Telangiectasia
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Glucophage
EMD SeronoApproved
N-Acetyl-L-Leucine
IIntraBio Inc
Phase 3
Nicotinamide ribonucleoside
UUniversity Hospital, Akershus
Phase 2
Nicotinamide Riboside
UUniversity of Oklahoma
Preclinical
Prevenar
GSKPreclinical
Pneumovax
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nicotinamide ribonucleoside. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity Hospital, Akershus